Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

PR71499

BAGSVAERD, Denmark, Dec. 11 /PRNewswire=KYODO JBN/ --

Results published in Diabetes, Obesity and Metabolism   

Newly published data from real-world European clinical practice has shown that

Xultophy(R) (insulin degludec/liraglutide) significantly reduced blood sugar

levels in people with type 2 diabetes after six months.[1] The study looked at

people with type 2 diabetes who were treatment-naïve or who had been switched

to treatment with Xultophy(R)from any combination of oral antidiabetic drugs,

glucagon-like peptide-1 (GLP-1) analogues, and/or insulin regimens in

real-world clinical practice.[1]

In the study population, Xultophy(R) delivered a significant overall decrease

in mean blood sugar (HbA1c) of 0.9% to 7.5% at six months. Regardless of which

treatment the study participants were switched from, the average decrease in

blood sugar was significant.[1] The average dose of Xultophy(R) was 30 dose

steps (representing 30 units of insulin) at six months, significantly lower

than 50 dose steps which is the maximum approved dose of Xultophy(R).[1]

"It's exciting to see that Xultophy(R) delivers significant benefits to people

with type 2 diabetes in such a short period of time and in a real-world

setting, providing better blood sugar control with just one injection per day

regardless of previous treatment," said Mads Krogsgaard Thomsen, executive vice

president and chief science officer at Novo Nordisk.

Hypoglycaemia (low blood sugar) rates were reduced by 82% in the six month

period after initiating Xultophy(R), compared to the six month period before.

Furthermore, average body weight was significantly reduced by 0.7 kg after six

months of treatment vs baseline.[1]

About the EXTRA study   

The European Xultophy(R) Treatment Retrospective Audit (EXTRA) study was a

European, multicentre, retrospective chart review which included 611 people

with type 2 diabetes 18 years of age, who started on Xultophy(R) at least six

months prior to the start of the study. Blood sugar levels, body weight and

rate of hypoglycaemic events were measured at baseline (up to six months before

starting on Xultophy(R)) and at 3, 6, 9 and 12 months after initiating

Xultophy(R). Data was collected from clinics in Germany (n=450), Switzerland

(n=84), the UK (n=44), Austria (n=19) and Sweden (n=14).[1]

The study was published in the peer-reviewed journal Diabetes, Obesity and

Metabolism.[1]

About Xultophy(R)

Xultophy(R) is a once-daily single injection fixed-ratio combination of

long-acting insulin degludec and the glucagon-like peptide-1(GLP-1) receptor

agonist liraglutide in one pen. It is indicated for the treatment of adults

with type 2 diabetes mellitus to improve glycaemic control in combination with

oral glucose-lowering medicinal products when these alone or combined with a

GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic

control. Xultophy(R) can be administered at any time of the day with or without

meals, preferably at the same time of the day.[2]

About Novo Nordisk  

Novo Nordisk is a global healthcare company with more than 90 years of

innovation and leadership in diabetes care. This heritage has given us

experience and capabilities that also enable us to help people defeat other

serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in

77 countries and markets its products in more than 165 countries. For more

information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube  

References   

1.    Price H, Bluher M, Prager R, et al. Use and effectiveness of a

fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a

real-world population with type 2 diabetes: Results from a European,

multicentre, retrospective chart review study. Diabetes Obes Metab. 2017.

http://dx.doi.org/10.1111/dom.13182.

2.    EMA. Xultophy(R) Summary of Product Characteristics. Available at:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002647/WC500177657.pdf.

Last accessed: December 2017.

Further information  

Media:      

Katrine Sperling  

+45-4442-6718  

krsp@novonordisk.com

Asa Josefsson  

+45-3079-7708  

aajf@novonordisk.com

Investors:      

Peter Hugreffe Ankersen  

+45-3075-9085  

phak@novonordisk.com

Hanna Ogren  

+45-3079-8519  

haoe@novonordisk.com

Anders Mikkelsen  

+45-3079-4461  

armk@novonordisk.com

Christina Kjaer  

+45-3079-3009  

cnje@novonordisk.com

Kasper Veje (US)  

+1-609-235-8567  

kpvj@novonordisk.com

Source: Novo Nordisk